Serplulimab is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC Serplulimab is the first and only anti-PD-1 mAb approved in the European Union (EU) ...

The number of lung cancer diagnoses amongst people who have never smoked is increasing globally, according to the World ...

9, 2025 — Researchers have shown that a test called ORACLE can predict lung cancer survival at the point of ... New, Rare Type of Small Cell Lung Cancer Identified Sep. 11, 2024 — A team ...

Data from the Phase 3 PALOMA-3 study showed non-inferiority to intravenous administration meeting both co-primary pharmacokinetic (PK) endpoints, as well as a five-fold reduction in infusion-related ...

Media Release Marking Immutep's transition to a Phase III biotech, the Company's pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) received first regulatory approvalMature da ...

Media ReleaseMarking Immutep’s transition to a Phase III biotech, the Company’s pivotal TACTI-004 trial in first-line non-small cell lung cancer ...

High disease control rate and strong interim safety results observed in pancreatic cancer patients across three trials exploring the use of ...

Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve statistical significance for overall survival in patients with advanced ...

Another study of those with squamous cell carcinoma found that it took eight years for the cancer cells ... Symptoms that should prompt calling your healthcare provider for a checkup include: The five ...

Volrustomig is under clinical development by AstraZeneca and currently in Phase III for Squamous Non-Small Cell Lung Cancer. According to GlobalData, Phase III drugs for Squamous Non-Small Cell Lung ...

Lung cancer survival without treatment is shorter than survival with treatment. People with untreated non-small cell lung cancer—the most common type—typically live between five and 12 months after ...

Non-small cell lung cancer (NSCLC) is still the disease with the highest incidence rate among malignant tumors, in which NSCLC under N2 stage has obvious survival differences among different patients ...